OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Diplopia and Ptosis in an Older Woman	811
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	509
Somebody to Love	509
Error in Author Name	378
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	307
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	301
Equipping AI for Unbiased and Inclusive Neurology	273
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	262
Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials	253
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	245
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio	245
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	239
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	218
Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke	212
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	202
Efficacy and Safety of Ecopipam for Tourette Syndrome	202
The Machine Is Just as Loud	191
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	182
Automated Imaging Differentiation for Parkinsonism	177
Origin of Transthyretin in Cerebral Amyloid Angiopathy	170
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	168
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	162
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	152
JAMA Neurology	142
JAMA Neurology	141

Is It Really Itching?	140
The Neurologist’s Imperative in Brain Death	136
Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis	136
External Carotid Artery Angioplasty Based on Ultrahigh-Resolution Photon-Counting CTA	133
Endovascular Therapy for Basilar Occlusions—The ATTENTION Trial	133
Time to Change the Current Clinical Classification of Multiple Sclerosis?	132
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	132
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	131
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	129
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	127
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	125
Thrombolysis With Tenecteplase for Minor Disabling Stroke	125
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	124
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	123
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	121
Error in Abstract	118
Error in Additional Contributions	118
Histologic Anatomy of Neurocysticercosis	118
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	113
Genetic Testing by Age at Onset in Parkinson Disease	113
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	111
Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation	110
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	106
Error in Figure	98
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	97
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	96
Is It Really Itching?—Reply	95
JAMA Neurology	93
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	93
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	91
Do Neurologists Need a Goldwater Rule?	90
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	90
Five Years of Ublituximab in Multiple Sclerosis	90
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	90
Self-Reported Seizure Durations	88
Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy	88
Wind Swirl Pattern on Density Spectral Array in Anti-GABAB Receptor Encephalitis With Amnestic Seizures	86
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease	85
Interhemispheric Bullet Migration—A Surgical Dilemma	85
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	85
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	85
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	83
Role of the X Chromosome in Alzheimer Disease Genetics	82
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	82
Error in the Strengths and Limitations	81
Error in Text	81
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	78
Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials	77
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	77
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	77

JAMA Neurology	76
Perceived CTE and Suicidality—Is Perception Reality?	75
Error in Text	75
Error in Figures	74
Error in Key for Figure 3	73
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	72
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	72
A 62-Year-Old Man With Progressive Limb Weakness, Involuntary Movements, and HyperCKemia	71
AI Devices in Neurology—Moving From Diagnosis to Prognosis	70
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	69
“The Triage of Privilege” Factual Concerns	69
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	68
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	68
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	67
Error in Author’s Name	67
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	66
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	65
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	65
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	64
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	64
The New Era of Automated Electroencephalogram Interpretation	63
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	63
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	63
Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B	62
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	62
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	61
Superficial Siderosis and a Spinal Cord Cleft	61
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	61
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	59
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage	59
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	59
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	59
Burden of Central Nervous System Cancer in the United States, 1990-2021	58
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	58
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	58
Possible Explanations for Hearing Loss in Parkinson Disease	58
Error in Title	58
Benefits and Risks of Periconceptional Folic Acid Supplementation	57
Autism and Parkinsonism—Terminology and Confounding	55
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	55
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	54
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	54
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	53
IWG and AA Criteria—Where the Differences Matter—Reply	53
Repairing Our View of Dementia	53
SARS-CoV-2 Vaccination and Neuroimmunological Disease	52
Abdominal Clonus in the Setting of a T5 Spinal Cord Injury	52
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	52
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	51
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	51
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	50
Coma Prognostication After Acute Brain Injury	50
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	50
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	50
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention	50
Association Between Acute Myocardial Infarction and Cognition	49
Addition of Nonauthor Collaborators and a Supplement	49
JAMA Neurology	48
Views From Both Sides of the White Coat	47
Monogenic Stroke—Can We Overcome Nature With Nurture?	47
The Perils and Pitfalls of Global Engagement	47
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	47
Errors in Figure 2 and the Short Title	46
How Is the X Chromosome Involved in Alzheimer Disease?	46
Error in Author Affiliation	46
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	45
The Self-Test	45
A Test of the Alzheimer Disease Framework—Did It Pass?	45
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	45
Maternal Pregnancy Outcomes and Offspring Risk of Adult-Onset Multiple Sclerosis	45
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	44
Incidence and Risk Factors of Epilepsy Among Older Adults in the US Medicare Population	44
Complete Remission of Cavin-4 Immunoglobulin G Rippling Muscle Disease After Rituximab Therapy	44
Medical Forecasting—A Skill Set Worthy of Attention	44
Modern Neurology Training Is Failing Outpatients	43
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	43
Hypertension With High-Risk Features in Cryptogenic Stroke	43
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	43
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	42

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	42
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	42
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	42
Aberrant Left-to-Right Fusion of the Oculomotor Nerve	42
JAMA Neurology	41
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	41
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	41
Dietary Patterns and Indicators of Cognitive Function	41
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	41
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	40
Acute Ischemic Stroke Care Quality Improvement	40
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	39
JAMA Neurology	39
Error in Figures 2 and 3	39
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	38
Venture Capital Investment in Neurology Companies	38
Error in Open Access Status	38
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	38
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	38
Asymptomatic Carotid Stenosis—Is Medical Therapy Enough?	37
2024 Diagnostic Criteria for Multiple Sclerosis—A Unified Approach	37
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	36
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	36
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	36
Neurologic Complications of Smallpox and Monkeypox	36
JAMA Neurology	36
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	36
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	36
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	35
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	35
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	35
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	35
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	35
Batoclimab vs Placebo for Generalized Myasthenia Gravis	35
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	35
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	34
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	34
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	34
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	34
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	34
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	34
Paused—A Residency Interrupted	33
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	33
Entering Medicine as a Physician and a Patient	33
Risk Factors for Young-Onset Dementia in the UK Biobank	33
A Funeral for a Neurologist	33
JAMA Neurology Editorial Fellowship	32
A New Dystonia Phenotype in Wilson Disease	32
Remembering the Physician’s Humanity—Physicians Are Humans Too	32
Pattern of Recurrent Nontraumatic Intracerebral Hemorrhage—Reply	32
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	32
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	31
JAMA Neurology Peer Reviewers in 2025	31
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	31
Intramedullary Hemorrhage Causing Quadriplegia in the Setting of a Type B Aortic Dissection	31
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	31
Butter Yellow—A Soft Hue With Neurological Implications	31
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	30
Uniform Amyloid Thresholds Across Populations	30
Kelch-Like Protein 11 Antibody-Associated Paraneoplastic Encephalitis	30
Rethinking the Menopause Transition and Multiple Sclerosis Progression	30
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	29
Lecanemab Treatment in a Specialty Memory Clinic	29
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	29
Phenoconversion in Pure Autonomic Failure	29
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	29
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	28
Precision Antisense Oligonucleotide Therapy Amenability for Infantile Genetic Epilepsies	28
Error in Figure 2B	28
Error in Title	28
Iatrogenic Cerebrospinal Fluid–Venous Fistula	28
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	28
Error in Figure 1	28
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	28
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	27
Error in Figures	27
Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome	27
Cavernous Sinus Dural Arteriovenous Fistula With Ocular Congestion and Proptosis	27
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	27
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	27
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	27
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	27
Anticoagulation in ESUS—Back From the Dead?	27
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	26
Diminishing Returns of Novel Autoantibody Discovery in Encephalitis	26
Pressure-Triggered Dystonia in a 35-Year-Old Woman	26
Gadolinium-Enhanced Aneurysm Wall Imaging and Risk of Intracranial Aneurysm Growth or Rupture	26
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	26
Neurological Teleconsultations in General Practice	26
The Cynicism of the Seronegative	25
JAMA Neurology—The Year in Review, 2023	25
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	25
Sex Differences in Case-Fatality Rates of Stroke—Reply	25
JAMA Neurology	25
Error in the Author Affiliations	25